Vasoconstrictive properties of the 5HT1B/1D agonists:: response to Dahlof and Mathew

被引：0
作者：
Goldstein, D [1 ]
机构：
[1] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 1999年 / 19卷 / 05期
关键词：
D O I：
10.1177/033310249901900503
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：536 / 536
页数：1
相关论文
共 9 条
[1]   Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan [J].
Dahlof, CGH ;
Falk, L ;
Risenfors, M ;
Lewis, CP .
CEPHALALGIA, 1998, 18 (08) :546-551
[2]   Cardiovascular safety of 5HT1B/1D agonists -: Is there a cause for concern? [J].
Dahlof, CGH ;
Mathew, N .
CEPHALALGIA, 1998, 18 (08) :539-545
[3]  
MACINTYRE PD, 1992, BRIT J CLIN PHARMACO, V34, P541
[4]   EFFECT OF SUBCUTANEOUS SUMATRIPTAN, A SELECTIVE 5HT1 AGONIST, ON THE SYSTEMIC, PULMONARY, AND CORONARY CIRCULATION [J].
MACINTYRE, PD ;
BHARGAVA, B ;
HOGG, KJ ;
GEMMILL, JD ;
HILLIS, WS .
CIRCULATION, 1993, 87 (02) :401-405
[5]   The reporting sensitivities of two passive surveillance systems for vaccine adverse events [J].
Rosenthal, S ;
Chen, R .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1995, 85 (12) :1706-1709
[6]  
SWAN L, 1997, CEPHALALGIA, V17, P428
[7]  
*US FDA, 1997, SUMM BAS APPR ZOLM
[8]  
*US FDA, 1998, SUMM BAS APPR NAR ND
[9]  
*US FDA, FREED INF SUM ADV EV
1